CSIMarket
 
Mediwound Ltd   (MDWD)
Other Ticker:  
 
 
Price: $16.0000 $0.90 5.960%
Day's High: $16.02 Week Perf: -1.66 %
Day's Low: $ 14.99 30 Day Perf: 25.59 %
Volume (M): 31 52 Wk High: $ 17.25
Volume (M$): $ 496 52 Wk Avg: $10.52
Open: $14.99 52 Wk Low: $7.10



 Market Capitalization (Millions $) 433
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 22
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 1

Mediwound Ltd
MediWound Ltd is a biopharmaceutical company that specializes in developing and commercializing novel products for the treatment of severe burns and chronic wounds. Their flagship product, NexoBrid, is an enzymatic debridement agent that significantly reduces the need for surgical intervention in burn patients. It works by selectively removing dead tissues, allowing for faster healing and reduced scarring. MediWound also offers other wound care products, such as EscharEx for chronic wounds.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Revolutionizing Burn Treatment: FDA Acceptance Marks a New Dawn for Pediatric Burn Patients with NexoBrid

Published Tue, Jan 9 2024 12:00 PM UTC

MediWound Ltd, an innovator in burn and wound care treatments, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplement to the Biologics License Application (BLA) for NexoBrid. This medical breakthrough, if approved, aims to transform the burn treatment realm by serving as an effective, non-surgical solution for pediatric...

Financing Agreement

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army

Published Thu, Dec 28 2023 12:00 PM UTC

MediWound Awarded $6.7 Million to Advance NexoBrid as a Non-Surgical Field Care Solution; R&D Budget Increased to $14.4 Million
MediWound, a leading biopharmaceutical company specializing in innovative wound healing solutions, has recently been awarded an additional $6.7 million to advance the development of NexoBrid as a non-surgical field care solution. With this fund...

Product Service News

Breaking New Ground in Wound Care: MediWound's EscharEx Exceeds Expectations and Elevates Wound Treatment Standards

Published Thu, Dec 21 2023 1:00 PM UTC

In a recent peer-reviewed publication, MediWound Ltd, a leading biotechnology company specializing in innovative wound healing solutions, announced the successful results of a comprehensive study evaluating their flagship product, EscharEx. The findings highlight the safety and effectiveness of EscharEx, suggesting that it can exceed the conventional limitations of enzymatic...






 

Mediwound Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com